Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma

Contributing sentiments towards policy:

47% : President Donald Trump issued an executive order that partly targets a key provision of the Inflation Reduction Act that allows Medicare to negotiate drug prices with manufacturers.
47% : Changing the law "would come at a cost to Medicare and beneficiaries by giving drug companies 4 additional years of setting their own prices on these drugs prior to being eligible for negotiation by the federal government, unless combined with other changes to prevent higher spending," the analysis said.
46% : Executives said they are seeing elevated medical costs in Medicare, but those are priced into their premiums.
44% : As shake-ups in Medicare continue, bigger may not be a big advantage.
42% : UnitedHealth has navigated the Biden-era reimbursement pressure on Medicare plans better than its peers over the last few years, but as rivals like Humana and Centene cut back on their footprints this year, UnitedHealth picked up new members who have required a lot more outpatient care than expected.
19% : In the wide-ranging order, Trump directed Health and Human Services Secretary Robert F. Kennedy Jr. to work with Congress to modify a piece of the Medicare drug price negotiation rules, which differentiate between small-molecule drugs and biologic medicines.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.